J&J Revitalizes Consumer Biz; Thrives On Pharma Strength In First Quarter
This article was originally published in The Pink Sheet Daily
The healthcare conglomerate reported strong sales in the first quarter that were largely due to growth of its pharmaceutical business, but got an extra boost from the continued renewal of its consumer products portfolio.
You may also be interested in...
J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
The global pharmaceutical giant has had several new products hit the market in the last two years that have allowed it to retain a global leadership position despite tough economic circumstances and issues with its consumer segment.